Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Alteogen (196170) – Shinhan Securities | Halozyme Patent Invalidated · Key Overhangs Materially Eased · Target Price Raised / 2026-05-14 Research
  • [Research] LIG D&A (079550) – Shinhan Securities | Structural Export Growth · Order Pipeline · Long-term Demand / 2026-08-07 Research
  • About | Korea Equity Lens About
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | ADR Listing · Valuation Gap · Re-rating / 2026-03-25 Research
  • [Research] Samsung SDI (006400) – DS Investment & Securities | Core Profitability Turnaround · Robust ESS Backlog · Humanoid Physical AI Expansion / 2026-07-31 Research
  • [Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM Demand · AI Accelerator Diversification · Profitability / 2026-01-21 Research
  • [Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10 Research
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 5 H2 Revenue Recognition · US Site Cost Control · 2026 Profitability Defense / 2026-01-07 Research

[Research] SK hynix (000660 / SKHY) – Meritz | ADR Listing · Valuation Discount · Re-rating / 2026-04-23

Posted on April 23, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Meritz Securities

Analyst : Sun-woo Kim / RA : Seo-hyun Woo

Investment Rating : Buy (Maintained)

Target Price : KRW 2,000,000 (Upgraded)

Core Momentum : Record profitability and a substantial valuation discount to global memory peers strengthen SK hynix’s appeal to global investors, while the planned US ADR listing provides a catalyst for a progressive valuation re-rating.

📊 1. [Valuation & Key Financial Metrics]

  • Equity Research Date: April 23, 2026
  • Investment Rating: Buy / Target Price (12M): KRW 2,000,000 (Upgraded)
  • Current Price (as of 4/23): KRW 1,225,000 / Upside Potential: 63.3%
  • KOSPI: 6,475.81pt / Market Capitalization: KRW 873,060.4 billion
  • Shares Outstanding: 71,270k shares / Float Ratio: 75.04%
  • Foreign Ownership: 53.05% / 52-Week High / Low: KRW 1,225,000 / KRW 177,500 / Average Trading Value: KRW 4,411.65 billion
  • Major Shareholders: SK Square and 6 others 20.50%, National Pension Service 7.50%, BlackRock Fund Advisors and 14 others 5.12%
  • FY 2026E Estimates: Revenue KRW 322,677 bn, Operating Profit KRW 250,125 bn, Net Income KRW 216,782 bn, EPS KRW 297,777, PER 4.1x, PBR 2.66x, ROE 95.1%
  • FY 2027E Estimates: Revenue KRW 468,347 bn, Operating Profit KRW 382,326 bn, Net Income KRW 329,425 bn, EPS KRW 452,505, PER 2.7x, PBR 1.36x, ROE 66.4%

🚀 2. [Market Opportunities & Business Outlook]

  • SK hynix’s 1Q26 operating profit recorded KRW 37.6 trillion, up 96% from the previous quarter’s KRW 19.2 trillion, meeting internal estimates. 1Q26 DRAM and NAND operating margin estimates stand at 78% and 52% respectively, with commodity DRAM operating margins reaching an industry-leading 86%.
  • Sales volumes are expected to rebound significantly in the upcoming quarter due to seasonality and regional characteristics of the Dalian fab, while flexible pricing policies are likely to shift toward aggressive strategies recovering market price levels.
  • The recent earnings call announcements are interpreted as conservative decisions to eliminate legal uncertainties regarding financial and capital changes tied to the US SEC ADR listing process. The final decision on the ADR listing will be made within June, and following demand surveys from US and global investors, a rapid listing process is anticipated.
  • SK hynix is highly likely to be perceived as an exceptionally attractive investment destination for US investors due to 1) absolute valuation undervaluation (2026E ROE 95.1% vs P/B 2.66x), 2) relative valuation discounts (Micron at 5.31x vs hynix at 2.66x), 3) being the top pure player within the up-cycle, and 4) being the largest capacity expansion enterprise this year.
  • Amid the proliferation of Agentic AI, the industry status of memory players is rising. With CPU-centric computing power increasingly emphasized alongside GPUs, memory shortages in 2027 continue to intensify.

📝 Editor’s Comment (Perspective & Thesis Verification)

The analyst evaluates SK hynix as a prime semiconductor leader capturing structural growth, underpinned by record-breaking profitability and potential global re-rating catalysts through a US ADR listing and shareholder return policies. This perspective highlights that a step-by-step re-rating phase is actively unfolding within the current industry up-cycle.

To determine whether this investment thesis is actively unfolding, key monitoring items include tracking the progress of the US ADR listing decisions slated within June, post-listing investor demand surveys, subsequent sales volume recoveries, and worsening memory supply shortages heading into 2027. These developments can be tracked through corporate earnings reports, regulatory disclosures, and official IR materials.

📢 Disclaimer & Source Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports. Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor. Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – DS Investment | Memory ASP · High-Value Product Mix · Supply Tightness / 2026-04-23
Next Post: [Research] SK hynix (000660 / SKHY) – IBK Securities | AI Servers · Full-Stack Memory · NAND Demand / 2026-04-24

Related Posts

  • [Research] Samsung Electro-Mechanics (009150) – IBK Securities | CAPEX Surge · Foreign Inflows · Target Price Upgrade / 2026-07-16 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · HBM Market Share · Earnings Growth / 2026-07-01 Research
  • [Research] Samsung Biologics (207940) – Hana Securities | Post-Spinoff Profitability · Record KRW 6.8T Orders · Plant 6 Groundbreaking Visibility / 2026-01-07 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | SDC Stake Monetization Pursuit · North America ESS & Europe EV Order Acceleration · Operating Profit Turnaround / 2026-04-29 Research
  • [Research] Samsung SDI (006400) – Kiwoom Securities | ESS & BBU Momentum · Europe Market Share Recovery · 4Q26 Turnaround / 2026-04-29 Research
  • [Research] LIG D&A (079550) – Kiwoom Securities | Defense Export Expansion · GR Turnaround · 2026E Upward / 2026-02-19 Research
  • [Research] Samsung SDI (006400) – SK Securities | Plant Utilization Recovery · North America ESS Expansion · AMPC Benefits / 2026-04-29 Research
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | MLCC Price Hikes · Server Product Mix · Target Price Revision / 2026-07-31 Research
  • [Research] Samsung Electro-Mechanics (009150) – Shinhan Securities | High-Value Order Expansion · Valuation Re-rating · Capacity Utilization / 2026-07-02 Research
  • [Research] ABL Bio (298380) – DS Investment & Securities | ABL001 Data Failure · Grabody Platforms · Intrinsic Value / 2026-04-28 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | LTA · Capex Discipline · Cycle Stability / 2026-01-28 Research
  • [Research] LigaChem Biosciences (141080) – Shinhan Securities | ConjuALL · Clinical Milestones · Big Pharma L/O / 2026-03-24 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | Supply Tightness · LTA · Shareholder Returns / 2026-07-30 Research
  • [Research] LigaChem Biosciences (141080) – Kyobo Securities | Pipeline Clinical Progress · IND Filings · Tech Transfer / 2026-04-01 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme